Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab PK Comparability Study (CMC2 vs CMC3)
NCT06054425Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2023
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of risankizumab in plaque psoriasis, psoriatic arthritis (PsA), Crohn's disease and 1 more (2 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Serum Concentration, Time to Maximum Observed Serum Concentration and 5 more. Started Nov 2023; status: completed.
02
Drugs
risankizumab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06054425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06054425.